GLOBALT Investments LLC / GA 13F: Cuts AZN Stake by $4.3M
Key Points
- GLOBALT Investments cut its position in AstraZeneca by 26,752 shares, bringing its total to 2,406 shares valued at about $388,497.
- The fund's reported value for its AstraZeneca holdings is approximately $1.68 billion, representing about 0.02% of its entire portfolio.
- AstraZeneca's stock recently traded around $170.08, which is about equal to its closing price on the filing date.
Get AstraZeneca PLC text alerts
We text you when insiders, Congress, analysts or big funds move on $AZN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AstraZeneca PLC alert may contain errors. Disclosures
On October 27, 2026, GLOBALT Investments LLC reduced its stake in AstraZeneca PLC (AZN) by 26,752 shares. In its latest Form 13F filing with the SEC, the fund disclosed that it now holds 2,406 shares, which are valued at approximately $388,497.
AZN
AstraZeneca PLC
Where AstraZeneca Fits in GLOBALT Investments' Portfolio
GLOBALT's AstraZeneca position now accounts for about 0.02% of its total reported value of around $1.68 billion. This reduction marks a significant decrease of about 91.7% in the number of shares held compared to the previous quarter.
Other Institutional Activity in AstraZeneca
Investor AB holds a substantial position in AstraZeneca with 51,587,810 shares valued at about $8.77 billion. Capital International Investors increased its stake by 182,287 shares, bringing its total to 34,576,070 shares worth approximately $5.88 billion. Meanwhile, Legal & General Group PLC reduced its holdings by 100,819 shares, ending with 25,750,245 shares valued at around $4.38 billion.
AstraZeneca PLC Stock Down 1.2%
AstraZeneca's stock recently traded around $170.08, which is approximately equal to its closing price on October 27, 2026. The shares are currently above their 50-day moving average by about 3.9% but below the 200-day average by 5.7%. They are also 20% below the 52-week high of $212.71.
Recent Earnings
AstraZeneca reported trailing twelve-month revenue of approximately $61.37 billion, with an earnings per share (EPS) of $6.69. The company has a net margin of 17.0% and a return on equity (ROE) of 22.0%. The next earnings report is scheduled for October 30, 2026.
Dividend
AstraZeneca pays an annual dividend of $3.20 per share, which gives it a yield of approximately 1.88%. The dividend payout ratio stands at 46.9%.
Analysts Set New Price Targets
On August 24, 2026, CICC initiated coverage on AstraZeneca with an "Outperform" rating and a price target of $198. The consensus recommendation for the stock is a "buy" with a mean price target of $206.66 based on 12 analyst opinions.
About AstraZeneca
AstraZeneca PLC is a biopharmaceutical company based in Cambridge, United Kingdom. It focuses on the discovery, development, manufacture, and commercialization of prescription medicines, particularly in the healthcare sector.
Bottom Line
Investors should keep an eye on AstraZeneca's upcoming earnings report on October 30, 2026, and monitor any further changes in institutional holdings as the market evolves. This filing reflects GLOBALT's significant reduction in its position in the company.
Related Filing Alerts
Source: GLOBALT Investments LLC / GA's 13F filing on $AZN (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts